Highlights

• “Symtuza, of course, I use that as well, again a high barrier to resistance, well tolerated, good efficacy. The problem with Symtuza is that sometimes it has more drug interactions than I have with Biktarvy, andsometimes  I just get concerned about using a protease inhibitor, and perhaps a little bit of an impact on the bits associated with that, and also darunavir has an increased risk for myocardial infarction. 
• “Very favorable [thoughts on Biktarvy], I use it a lot, it is probably the regimen I use the most, if anything. It is well tolerated, it has good outcomes, I have seen patients with really no significant problems, very favorable drug interactions profile.”

   

• “Zero resistance reported is a huge advantage, I mean that gives me a lot of confidence that I can use it [Biktarvy] in a wide range of patients without concern that they develop resistance. It is unboosted, which is also another big advantage, I do not have to worry about impact at all on hepatic function.”